Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Gets Price Target Bump from Wedbush

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target boosted by investment analysts at Wedbush from $99.00 to $102.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush‘s price objective would suggest a potential upside of 14.79% from the company’s current price.

Several other research analysts also recently weighed in on the stock. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Canaccord Genuity Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. lifted their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $96.86.

Kiniksa Pharmaceuticals International Trading Down 0.4%

Shares of NASDAQ KNSA traded down $0.34 during mid-day trading on Wednesday, hitting $88.86. 135,386 shares of the company traded hands, compared to its average volume of 688,632. Kiniksa Pharmaceuticals International has a 1 year low of $36.56 and a 1 year high of $90.80. The business has a 50 day moving average of $78.23 and a two-hundred day moving average of $59.23.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. Sell-side analysts predict that Kiniksa Pharmaceuticals International will post 1.37 EPS for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CAO Michael Megna sold 4,600 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the sale, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at $2,333,678.60. This trade represents a 13.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 51.98% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP grew its position in Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after acquiring an additional 134 shares in the last quarter. Curry Webb Wealth Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth $29,000. KBC Group NV acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $34,000. Nykredit A S bought a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at $34,000. Finally, USA Financial Formulas bought a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at $69,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Strong earnings and revenue beat: Kiniksa reported third-quarter adjusted earnings of $0.56 per share, above the $0.32-$0.37 analyst estimates and up from $0.23 a year earlier. Revenue reached $285.97 million, exceeding the $260.66 million consensus estimate. Kiniksa Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Higher revenue outlook: Management raised expected 2026 ARCALYST net product revenue to $1.045 billion-$1.050 billion, or more than $1.045 billion, signaling continued confidence in demand for the recurrent pericarditis treatment. Kiniksa Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Rapid ARCALYST growth: Third-quarter ARCALYST revenue rose approximately 58% year over year to $286 million, while penetration among patients with multiple recurrences reached 23%, supporting the company’s commercial growth story. Kiniksa Three Key Takeaways
• Positive Sentiment: Analyst price-target increase: Wells Fargo raised its target from $87 to $110 and maintained an “overweight” rating, implying roughly 24% upside from the referenced $88.62 price. Wells Fargo Raises Kiniksa Price Target
• Positive Sentiment: Pipeline progress: KPL-387 pivotal Phase 3 data are expected in the second half of 2027, providing a potential longer-term catalyst beyond ARCALYST.
• Neutral Sentiment: Reported short interest was listed at zero shares as of October 26, offering no measurable short-position signal, although the figure may reflect a reporting anomaly.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.